ArticleBreast cancer research : BCR2015
Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study.
Article in Breast cancer research : BCR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Plasma prolactin and breast cancer risk: a meta- analysis.Scientific reports · 2016Pooled it
- Nutrition Across the Life Course and Risk of Young-Onset Breast Cancer: Mechanisms, Evidence, and Prevention Opportunities.Nutrients · 2026Review
- Depression, antidepressant use, and breast cancer incidence in the Sister Study cohort.Breast cancer research : BCR · 2025Article
- Plasma prolactin and postmenopausal breast cancer risk: a pooled analysis of four prospective cohort studies.Breast cancer research : BCR · 2024Article
- Novel FFPE proteomics method suggests prolactin induced protein as hormone induced cytoskeleton remodeling spatial biomarker.Communications biology · 2024Article
- Procedural application of mode-of-action and human relevance analysis: styrene-induced lung tumors in mice.Critical reviews in toxicology · 2024Review
- The Cell Transformation Assay: A Historical Assessment of Current Knowledge of Applications in an Integrated Approach to Testing and Assessment for Non-Genotoxic Carcinogens.International journal of molecular sciences · 2023Review
- Pituitary tumors and the risk of other malignancies: is the relationship coincidental or causal?Endocrine oncology (Bristol, England) · 2022Review
- Increasing trends in in situ breast cancer incidence in a region with no population-based mammographic screening program: results from Zurich, Switzerland 2003-2014.Journal of cancer research and clinical oncology · 2019Article
- Mapping Mammary Tumor Traits in the Rat.Methods in molecular biology (Clifton, N.J.) · 2019Review
- Giant prolactinoma, germline BRCA1 mutation, and depression: a case report.Journal of medical case reports · 2018Article
- Inclusion of Plasma Prolactin Levels in Current Risk Prediction Models of Premenopausal and Postmenopausal Breast Cancer.JNCI cancer spectrum · 2018Article
- Serum anti-müllerian hormone levels in evaluation of chemotherapy effect on ovarian reserve in women with breast cancer. A follow-up study.Saudi medical journal · 2018Article
- Rat models of 17β-estradiol-induced mammary cancer reveal novel insights into breast cancer etiology and prevention.Physiological genomics · 2018Review
- Article
- Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study.Endocrine connections · 2017Article
- The relationship between serum levels of prolactin and growth hormone in the early postnatal period.Pediatric research · 2017Article
- Should Domperidone be Used as a Galactagogue? Possible Safety Implications for Mother and Child.Drug safety · 2017Article
- Bone metastasis risk factors in breast cancer.Ecancermedicalscience · 2017Review
- Antidepressant use and circulating prolactin levels.Cancer causes & control : CCC · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 1 institution in 2 countries.
Funding
Abstract
introductionThe relationship between circulating prolactin and invasive breast cancer has been investigated previously, but the association between prolactin levels and in situ breast cancer risk has received less attention.
methodsWe analysed the relationship between pre-diagnostic prolactin levels and the risk of in situ breast cancer overall, and by menopausal status and use of postmenopausal hormone therapy (HT) at blood donation. Conditional logistic regression was used to assess this association in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, including 307 in situ breast cancer cases and their matched control subjects.
resultsWe found a significant positive association between higher circulating prolactin levels and risk of in situ breast cancer among all women [pre-and postmenopausal combined, ORlog2=1.35 (95% CI 1.04-1.76), Ptrend=0.03]. No statistically significant heterogeneity was found between prolactin levels and in situ cancer risk by menopausal status (Phet=0.98) or baseline HT use (Phet=0.20), although the observed association was more pronounced among postmenopausal women using HT compared to non-users (Ptrend=0.06 vs Ptrend=0.35). In subgroup analyses, the observed positive association was strongest in women diagnosed with in situ breast tumors<4 years compared to ≥4 years after blood donation (Ptrend=0.01 vs Ptrend=0.63; Phet=0.04) and among nulliparous women compared to parous women (Ptrend=0.03 vs Ptrend=0.15; Phet=0.07).
conclusionsOur data extends prior research linking prolactin and invasive breast cancer to the outcome of in situ breast tumours and shows that higher circulating prolactin is associated with increased risk of in situ breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.